A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M.
Tsai DE, et al. Among authors: andreadis c.
Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185.
Clin Cancer Res. 2008.
PMID: 18765556
Clinical Trial.